- About the College
- Veterinary Medical Center
- Departments & Offices
This randomized, double-blind, active-control single-dose study addresses the hypothesis that ivabradine does reduce dynamic obstruction of the left ventricular outflow tract in cats with Hypertrophic cardiomyopathy (HCM).
Hypertrophic cardiomyopathy (HCM) is the most common heart disease in cats predisposing cats to the development of congestive heart failure (CHF), thromboembolic disease, and sudden death. Intolerance to episodes of fast heart rate induced by stress seems to be one of the most important trigger events leading to decompensation in previously stable cats with HCM. Control of heart rate is an important treatment strategy in asymptomatic cats with HCM. Currently, atenolol (a beta blocker) and diltiazem (a calcium channel inhibitor) are used to treat preclinical HCM. However, both drugs may induce adverse events including weakness, fainting, inappetence, cough, and weight loss. Ivabradine is a novel agent that selectively lowers heart rate, is clinically well tolerated in cats, and might become a new treatment option in cats with HCM. While the effects of Ivabradine on heart rate and cardiac function have been studied in cats, its effect on obstruction of the left ventricular outflow tract (a commonly seen pathologic phenomenon in cats with HCM) is unknown. We hypothesized that Ivabradine will have favorable effects on outflow tract obstruction in cats with HCM (reduction or complete elimination).
Your cat will undergo a general exam which includes a physical examination, a noninvasive blood pressure measurement, and a cardiac ultrasound study. Once completed, Ivabradine or active control will be administered, and the diagnostic procedures will be repeated.
Dr. Karsten Schober, DVM, PhD (Cardiologist) at 614.292.3551, ext. 48676 or E-mail: schober [dot] 4 [at] osu [dot] edu, or Dr. Keith Blass (blass [dot] 9 [at] osu [dot] edu) for further information.